Cancer Relevance and Scientific Rationale: Childhood cancer survivors are at a life-long risk of chronic health
conditions; by age 50, the cumulative incidence of life-threatening/fatal chronic health conditions is 53%. The
two leading causes of premature mortality in childhood cancer survivors are radiation-related subsequent
neoplasms (SNs) and anthracycline-related cardiac dysfunction (CD). Radiation and anthracyclines are both
used in >60% of children with cancer, and there are no plans in the foreseeable future to eliminate these agents.
Although there is a dose-response relation between radiation and SN and between anthracyclines and CD
(regardless of the underlying primary cancer), there is significant inter-patient variability in the risk, suggesting
the moderating role of genetic predisposition. The high burden of morbidity coupled with the inter-individual
variability in risk, suggests a need and an opportunity to identify patients at highest risk for treatment-related
morbidity, such that targeted interventions can be instituted. Broad Plan: This application harnesses and merges
novel concepts from the field of molecular biology, pharmacogenomics and cancer survivorship to identify cancer
patients by their personal risk of SN or CD. This award also attempts to understand the molecular pathogenesis
of these complications to inform future development of targeted prevention/therapeutic strategies. The necessary
infrastructure for the proposed research, including banked, annotated biospecimens (n=13,450) and pre-existing
collaborations with the necessary expertise will be leveraged in this application. The goals are to: i) develop a
risk prediction model for radiation-related SN and anthracycline-related CD in childhood cancer survivors; ii)
replicate the optimized model in an independent cohort of childhood cancer survivors; iii) apply the optimized
model to newly-diagnosed children with cancer to predict the risk of incident SN/CD; iv) determine the functional
relevance of the genetic signatures. Qualifications: I am the founding Director of the Institute for Cancer
Outcomes and Survivorship at the University of Alabama at Birmingham. I have over 20y of experience
conducting cancer outcomes research that bridges the fields of oncology, epidemiology and genetics. Since
2000, I have been charged with shaping the pediatric oncology survivorship research agenda within the
Children's Oncology Group – an NCI-supported clinical trials group, devoted exclusively to pediatric cancer
research across 220 centers. I am currently serving as chair-elect for the ASCO survivorship committee. I am a
Leukemia Lymphoma Scholar, a recipient of the Frank H Oski award, and am an elected member of the American
Society of Clinical Investigation, and the Association for American Physicians. I have been continuously funded
by NCI since 2000. With over 235 peer-reviewed publications and 15,220 citations (9,300 since 2012), my
Google Scholar H-INDEX is 66 (54 since 2012) and my i10-index is 182 (167 since 2012). I am fully committed
to improving the long-term health of our childhood cancer survivors, and I strongly believe that findings from this
application will accelerate the pace to reduce the burden of morbidity in this population.
If you are accessing this page during weekend or evening hours, the database may currently be offline for maintenance and should operational within a few hours. Otherwise, we have been notified of this error and will be addressing it immediately.
Please contact us
if this error persists.
We apologize for the inconvenience.
- The DCCPS Team.